TriSalus Life Sciences Warrant
TLSIW
5 hedge funds and large institutions have $798K invested in TriSalus Life Sciences Warrant in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
29% less funds holding
Funds holding: 7 → 5 (-2)
53% less capital inflows, than outflows
Capital inflows: $36.6K | Capital outflows: $78.3K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aristeia Capital
Greenwich,
Connecticut
|
+$36.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$78.2K |
| 2 |
Rockefeller Capital Management
New York
|
-$60 |
TLSIW Hedge Fund Activity: Q2 2026 in Review
5 of the 8,360 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences Warrant (TLSIW) for Q2 2026, worth a combined $798K — down 35% from $1.23M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of TLSIW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Aristeia Capital, adding an estimated $36.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $78.2K sold.
- 5 institutional investors held TriSalus Life Sciences Warrant (TLSIW) as of Q2 2026, down from 7 in Q1 2026.
- Funds reported $798K of TriSalus Life Sciences Warrant stock for Q2 2026, down 35% quarter-over-quarter.
- 0 funds opened new TriSalus Life Sciences Warrant positions in Q2 2026 and 2 closed out, a net change of -2 holders.
- The largest TriSalus Life Sciences Warrant buyer in Q2 2026 was Aristeia Capital, an estimated $36.6K added.
- The largest TriSalus Life Sciences Warrant seller in Q2 2026 was Citadel Advisors, an estimated $78.2K sold.
Based on aggregated 13F filings for Q2 2026.